Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ascendis Pharma Ads (ASND)

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ascendis Pharma A/S Receives Orphan Designation for TransCon(TM) hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon(TM) CNP at International Skeletal Dysplasia Society Meeting

- TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial -

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Three Investor Presentations in September

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

- TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials -

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Participation in August Investor Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 103.36 (+4.52%)
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon(TM) CNP in Children with Achondroplasia

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet medical needs, today announced the filing of an investigational...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon(TM) hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH -

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Reports Full Year 2018 Financial Results

- Rare disease endocrinology pipeline continues to advance, with

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 at 4:30...

ASND : 103.36 (+4.52%)
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced that the company will hold a conference...

ASND : 103.36 (+4.52%)
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

SNY : 45.94 (-0.50%)
RHHBY : 36.7300 (-0.22%)
PFE : 36.46 (unch)
ASND : 103.36 (+4.52%)
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism...

ASND : 103.36 (+4.52%)
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon(TM) hGH to a Daily Growth Hormone

- Oral presentation of results in pediatric growth hormone deficiency on behalf of investigators at ENDO 2019 -

ASND : 103.36 (+4.52%)
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock

Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASND : 103.36 (+4.52%)
Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Manulife Financial Corp (NYSE:MFC),...

MFC : 18.74 (+1.08%)
FNF : 45.75 (+0.66%)
HCCI : 26.82 (-0.48%)
ERIC : 9.11 (-0.76%)
ASND : 103.36 (+4.52%)
ASTE : 31.27 (+1.20%)
Company News For Mar 5, 2019

Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

ASND : 103.36 (+4.52%)
BIIB : 223.51 (+1.57%)
PLCE : 75.12 (-1.93%)
NITE : 25.41 (-0.04%)
TAK : 17.53 (+1.04%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.71 , AIZ +1.89 , SBAC +1.73 , SO +0.45 , WELL +0.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar